Clinical implications of FDG PETCT in cancer of unknown primaries

Author(s): Emily Vaughan, Shaunak Navalkissoor

Hospital: Royal Free London NHS Foundation Trust

Reference: RAD Magazine, 44, 519, 23-24


Cancer of unknown primary (CUP) has an incidence of 3.3% in the UK but this is falling, largely due to improvement in diagnostics, enabling underlying pathology to be identified and treated, therefore improving survival outcomes. F-18 FDG PETCT is increasingly being used to investigate for malignancy in patients in whom initial tests have proven inconclusive and is recommended by NICE for patients with cervical lymphadenopathy and suspicion of CUP with no primary identified on ENT endoscopy, or in patients with extra cervical presentation following discussion with the CUP team.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more